The Safety of Treating Women With Inflammatory Bowel Disease With Allopurinol and Low‐Dose Thiopurine During Pregnancy: A Single‐Center Experience

ABSTRACT Background Low‐dose thiopurine therapy in combination with allopurinol (LD‐THIO/ALLO) is a widely used treatment for inflammatory bowel disease (IBD). However, little is known about the effects of in utero exposure to this combination on pregnancy and birth outcomes. Methods In this retrospective, single‐center study, we included all patients with IBD treated with LD‐THIO/ALLO during conception and pregnancy between 2013 and 2023 at the Gastro Unit, Hvidovre Hospital, Copenhagen. Data were collected from electronic medical records and questionnaires. Results In total, 44 women with 62 pregnancies, including one twin pregnancy, and 59 live births were included. There was one spontaneous abortion and three induced abortions due to fetal genetic disorders, one because of trisomy 21 and two because of spinocerebellar ataxia. Obstetric complications occurred in eight pregnancies (13%), including preeclampsia, HELLP syndrome, hypertension, and/or gestational diabetes mellitus. Seven women (11%) had an IBD flare during pregnancy, none of which resulted in obstetric complications. Five children (9%) were born preterm, and four (7%) had low birth weight. No congenital malformations were reported. One child was born with facial nerve paralysis and was later diagnosed with hyper‐IgD syndrome. In total, 84% of the children were breastfed during maternal LD‐THIO/ALLO treatment. During the first year of life, one child had repeated infections and was transiently suspected of having an immune defect. Conclusions In this large, single‐center experience of LD‐THIO/ALLO treatment during pregnancy, no malformations or indications of increased risk of complications in pregnancy or birth were observed. Most children were breastfed, and no serious safety signals were reported in the first year of life. Treatment with LD‐THIO/ALLO appears to be safe during both pregnancy and breastfeeding.

Authors

Institutions

Publication Details

Journal
JCC Plus
Published
2026-06-18
DOI
https://doi.org/10.1002/jcc5.70050
Primary Topic
Pregnancy and Medication Impact
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Safety of Treating Women With Inflammatory Bowel Disease With Allopurinol and Low‐Dose Thiopurine During Pregnancy: A Single‐Center Experience

Signe Wildt, Andreas Munk Petersen, Marianne Kiszka‐Kanowitz, Klaus Theede et al.
JCC Plus
Pregnancy and Medication Impact
article

The Safety of Treating Women With Inflammatory Bowel Disease With Allopurinol and Low‐Dose Thiopurine During Pregnancy: A Single‐Center Experience

Signe Wildt, Andreas Munk Petersen, Marianne Kiszka‐Kanowitz, Klaus Theede, Inge Nordgaard-Lassen, Kavitha Sivananthan, Helle Kristensen, Gitte Pedersen, Johan Burisch, Ida Vind
article en

Abstract

ABSTRACT Background Low‐dose thiopurine therapy in combination with allopurinol (LD‐THIO/ALLO) is a widely used treatment for inflammatory bowel disease (IBD). However, little is known about the effects of in utero exposure to this combination on pregnancy and birth outcomes. Methods In this retrospective, single‐center study, we included all patients with IBD treated with LD‐THIO/ALLO during conception and pregnancy between 2013 and 2023 at the Gastro Unit, Hvidovre Hospital, Copenhagen. Data were collected from electronic medical records and questionnaires. Results In total, 44 women with 62 pregnancies, including one twin pregnancy, and 59 live births were included. There was one spontaneous abortion and three induced abortions due to fetal genetic disorders, one because of trisomy 21 and two because of spinocerebellar ataxia. Obstetric complications occurred in eight pregnancies (13%), including preeclampsia, HELLP syndrome, hypertension, and/or gestational diabetes mellitus. Seven women (11%) had an IBD flare during pregnancy, none of which resulted in obstetric complications. Five children (9%) were born preterm, and four (7%) had low birth weight. No congenital malformations were reported. One child was born with facial nerve paralysis and was later diagnosed with hyper‐IgD syndrome. In total, 84% of the children were breastfed during maternal LD‐THIO/ALLO treatment. During the first year of life, one child had repeated infections and was transiently suspected of having an immune defect. Conclusions In this large, single‐center experience of LD‐THIO/ALLO treatment during pregnancy, no malformations or indications of increased risk of complications in pregnancy or birth were observed. Most children were breastfed, and no serious safety signals were reported in the first year of life. Treatment with LD‐THIO/ALLO appears to be safe during both pregnancy and breastfeeding.

JCC PlusVol. 1(4)
University of Copenhagen (DK), Hvidovre Hospital (DK), Copenhagen University Hospital (DK)
Good health and well-being
Openalex Percentile: Top 5%
Pregnancy and Medication Impact
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.